Published: Fri, April 21, 2017
Health | By Jay Jacobs

Somewhat Positive Media Coverage Extremely Unlikely to Impact TherapeuticsMD (TXMD) Stock Price

Somewhat Positive Media Coverage Extremely Unlikely to Impact TherapeuticsMD (TXMD) Stock Price

The average numbers of shares are traded in a security per day, during the recent 3-month period.

07/08/2014 - FBR Capital Markets began new coverage on TherapeuticsMD, Inc. giving the company a " rating. Relative Strength Index (RSI) of the company is 33.37. The RSI oscillates between zero and 100.

Traditional interpretation and usage of the RSI is that RSI values of 70 or above indicate that a security is becoming overbought or overvalued, and therefore may be primed for a trend reversal or corrective pullback in price.

While taking a look at financials, we can look at a number of key indicators about TherapeuticsMD, Inc. (TXMD) is at 28.36. They now have a United States dollars 34 price target on the stock. The median estimate represents a 240.21% increase from the last price. This is the price at which the trader or investor wants to exit his existing position so he can realize the most reward. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Franklin Resources Inc. now owns 11,256,377 shares of the specialty pharmaceutical company's stock valued at $64,949,000 after buying an additional 981,231 shares during the last quarter. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target. Jefferies Group LLC restated a "buy" rating and set a $18.00 price objective on shares of TherapeuticsMD in a research report on Thursday, March 2nd. The average volume of a stock suggests the liquidity of a particular company. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Beta factor is used to measure the volatility of the stock. During the same quarter previous year, the company posted ($0.10) EPS. The analysts estimated EPS for the higher end at -0.09 and lower end at -0.15 while the year ago reported earnings per share was 0. Comparatively, TherapeuticsMD, Inc. posted earnings of $0 per share in the same quarter a year ago.

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. It is the "top line" or "gross income" figure from which costs are subtracted to determine net income. The firm earned $4.49 million during the quarter, compared to the consensus estimate of $5.91 million. It would take about 22.61 days to cover all short positions. Tracking most recent quarter period, Price to book (P/B) ration is at 8.48 and Price to cash per share ration is at 8.28. The company has a 50 day moving average price of $6.72 and a 200 day moving average price of $6.26.

A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year. They now have a Dollars 15 price target on the stock. The stock's 52-week range is $4.39 - $9.29.

05/08/2015 - TherapeuticsMD, Inc. was downgraded to "sell" by analysts at Zacks. The analyst recommendations from a month ago are 0 Buy, 5 Strong Buy, 0 Sell, 0 Hold and 0.

Oppenheimer Initiated its coverage for TherapeuticsMD, Inc. (TXMD) in a note sent to investors on 22-Nov-16. The stock went down -4.01% at some stage in past quarter. The total market capitalization remained at $225.25 billion.

Shares outstanding are recorded as 197.53 M and total shares floated are 154.76 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 9.30.

Like this: